US 12,473,578 B2
Carbonyl reductase, nucleic acid encoding same, and method for producing optically active compound using same
Takanobu Iura, Tokyo (JP); Yasumasa Dekishima, Tokyo (JP); Takeshi Sakamoto, Tokyo (JP); Mari Hara, Tokyo (JP); Hirotoshi Hiraoka, Osaka (JP); Harald Gröger, Bielefeld (DE); and Jieun Choi, Berlin (DE)
Assigned to UBE CORPORATION, Yamaguchi (JP)
Appl. No. 17/778,712
Filed by UBE CORPORATION, Yamaguchi (JP)
PCT Filed Nov. 20, 2020, PCT No. PCT/JP2020/043366
§ 371(c)(1), (2) Date May 20, 2022,
PCT Pub. No. WO2021/100848, PCT Pub. Date May 27, 2021.
Claims priority of application No. 2019-211797 (JP), filed on Nov. 22, 2019.
Prior Publication US 2023/0025343 A1, Jan. 26, 2023
Int. Cl. C12P 17/16 (2006.01); C12N 9/04 (2006.01)
CPC C12P 17/167 (2013.01) [C12N 9/0006 (2013.01); C12Y 101/01184 (2013.01)] 11 Claims
 
1. A carbonyl reductase variant comprising an amino acid sequence having at least 90% and less than 100% sequence identity to SEQ ID NO:1 and having carbonyl reductase activity, the variant comprising at least one or more mutation selected from the group of mutations consisting of:
(a) a mutation in which the 54th aspartic acid in SEQ ID NO: 1 is substituted by valine;
(b) a mutation in which the 157th methionine in SEQ ID NO: 1 is substituted by valine;
(c) a mutation in which the 170th alanine in SEQ ID NO: 1 is substituted by serine;
(d) a mutation in which the 211th isoleucine in SEQ ID NO: 1 is substituted by alanine or asparagine;
(e) a mutation in which the 214th methionine in SEQ ID NO: 1 is substituted by leucine; and
(f) a mutation in which the 249th methionine in SEQ ID NO: 1 is substituted by leucine.